文献速递药物相互作用药物不良反应与药物警戒

时机至关重要:通过FAERS信号检测结合共暴露时间优先排序药物相互作用

Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure.
PubMed 文献 · Drug Saf · 2024-04-30

本研究在FDA不良事件报告系统(FAERS)中开发一种纳入共暴露时间的比例失衡分析方法,以识别具有时间合理性的药物相互作用(DDI)信号,并用Lasso回归识别混杂因素。对122个含3例以上病例的三联组合分析后,优先排序出61个信号(50.0%),其中61.5%被列入EMA重要医学事件清单。

要点

  • 在比例失衡分析中纳入共暴露时间可提升DDI信号的时序合理性,减少假阳性。
  • 122个三联组合中优先排序61个信号(50.0%),涉及13种不良事件。

核心结论

  • 纳入共暴露时间的比例失衡分析方法能够优先排序具有时间合理性的DDI信号,提示该方法有潜力识别更可能被进一步验证的信号。

研究设计与样本

  • 在FDA不良事件报告系统(FAERS)中测试该方法,以CRESCENDDI阳性对照数据集作为真阳性DDI的主要来源。
  • 比例失衡分析考虑共暴露时间,时间合理性通过比例失衡信号累计报告数的拐点评估,潜在混杂因素用Lasso回归识别。
  • 对122个病例数超过3例的三联组合进行比例失衡分析。

主要发现

  • 优先排序出61个比例失衡信号(50.0%),涉及13种不良事件,其中61.5%被列入欧洲药品管理局(EMA)重要医学事件(IME)清单。
  • 检索到的混杂因素主要是其他合并用药。

临床怎么用

  • 在自发报告系统数据库的DDI信号检测中引入共暴露时间维度,可辅助优先关注具有时间合理性的信号以供进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Current drug-drug interaction (DDI) detection methods often miss the aspect of temporal plausibility, leading to false-positive disproportionality signals in spontaneous reporting system (SRS) databases. OBJECTIVE: This study aims to develop a method for detecting and prioritizing temporally plausible disproportionality signals of DDIs in SRS databases by incorporating co-exposure time in disproportionality analysis. METHODS: The method was tested in the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). The CRESCENDDI dataset of positive controls served as the primary source of true-positive DDIs. Disproportionality analysis was performed considering the time of co-exposure. Temporal plausibility was assessed using the flex point of cumulative reporting of disproportionality signals. Potential confounders were identified using a machine learning method (i.e. Lasso regression). RESULTS: Disproportionality analysis was conducted on 122 triplets with more than three cases, resulting in the prioritization of 61 disproportionality signals (50.0%) involving 13 adverse events, with 61.5% of these included in the European Medicine Agency's (EMA's) Important Medical Event (IME) list. A total of 27 signals (44.3%) had at least ten cases reporting the triplet of interest, and most of them (n = 19; 70.4%) were temporally plausible. The retrieved confounders were mainly other concomitant drugs. CONCLUSIONS: Our method was able to prioritize disproportionality signals with temporal plausibility. This finding suggests a potential for our method in pinpointing signals that are more likely to be furtherly validated.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Battini V, Cocco M, Barbieri MA, et al. Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure. Drug Saf. 2024. PMID: 38687463. doi:10.1007/s40264-024-01430-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。